Almirall acquires rights to new psoriasis drug in Europe

Almirall has entered a commercialization agreement with Danish MC2 Therapeutics, meaning the Spanish dermatology company will take on European sales of MC2's Wynzora cream for treating psoriasis.

MC2 Therapeutics has sold off the exclusive rights to selling the firm's new cream treating plaque psoriasis in Europe.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading